This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.
Dashboard: Filter Bricks
Main page content
This guide was drawn from HEALing Communities Study (HCS) learnings to-date and expert insights to provide guidance regarding implementation of ORCCA menu strategies.
The third supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. A compendium of resources for professionals who work with parents involved with child welfare.
The second supplemental to SAMHSA’s Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. This document contains information for pregnant people with a substance use disorder and professionals who provide services for them.
This document accompanies the Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and Their Infants publication. It offers information about child welfare systems and what the health care provider's role is in developing a Plan of Safe Care.
This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.
This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Displaying 1 - 10 out of 13